Stability and bifurcation analysis of an HIV model with pre-exposure prophylaxis and treatment interventions

被引:7
作者
Chazuka, Zviiteyi [1 ]
Mudimu, Edinah [1 ]
Mathebula, Dephney [1 ]
机构
[1] Univ South Africa, Coll Econ & Management Sci, Dept Decis Sci, Preller St, Pretoria, South Africa
关键词
Backward bifurcation; PrEP adherence; PrEP effectiveness; PrEP efficacy; Sensitivity analysis; Treatment interventions; BACKWARD BIFURCATIONS; TRANSMISSION; PREP; TUBERCULOSIS;
D O I
10.1016/j.sciaf.2023.e01979
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Oral pre-exposure prophylaxis (PrEP) is a highly effective method of HIV prevention. However, despite its effectiveness, the use of PrEP is not without challenges. These challenges include issues such as adherence, societal stigma, as well as accessibility and cost. PrEP effectiveness measures the drug's performance in the real world while efficacy measures the degree to which PrEP inhibits HIV infection and its transmission. In this paper, we address the problem of reduced effectiveness of PrEP, primarily due to non-adherence, and the impact on the dynamics of HIV infection. The study aims to determine the critical threshold of PrEP effectiveness required to avoid the occurrence of a backward bifurcation. The conditions for a stable infection -free equilibrium are stated. Through a rigorous analysis of the proposed mathematical model using Castillo-Chavez and Song's bifurcation theorem, it was found that backward bifurcation occurs when PrEP effectiveness falls below 100%. In contrast, if the effectiveness is 100%, which implies full adherence to PrEP, the model undergoes forward bifurcation. The existence of a backward bifurcation bears significant consequences, most notably the co-existence of the infection-free equilibrium and the endemic equilibrium. Under these circumstances, the eradication of HIV within a particular community becomes very difficult. The results of the numerical analysis demonstrate the important role of proper adherence in augmenting the effectiveness of PrEP and, consequently, curbing HIV transmission within communities. Nevertheless, intensive efforts are required to boost adherence to PrEP. Therefore, other HIV control measures need to be promoted to further reduce transmission.
引用
收藏
页数:21
相关论文
共 50 条
  • [21] Hospitalization is a missed opportunity for HIV screening, pre-exposure prophylaxis, and treatment
    William Bradford
    Hana Akselrod
    John Bassler
    Kelly W. Gagnon
    Greer Burkholder
    Joseph Edward Carpenter
    Alaina Steck
    Jillian Catalanotti
    Irene Kuo
    Keanan McGonigle
    William Mai
    Melissa Notis
    Christopher Brokus
    Sarah Kattakuzhy
    Elana Rosenthal
    Ellen F. Eaton
    Addiction Science & Clinical Practice, 19
  • [22] The Relationship Between HIV Pre-exposure Prophylaxis Stigma and Treatment Adherence Among Current HIV Pre-exposure Prophylaxis Users in the Southeastern U.S.
    Olivia T. Van Gerwen
    Ibrahim Yigit
    Kaylee B. Crockett
    Bulent Turan
    AIDS and Behavior, 2023, 27 : 1478 - 1485
  • [23] What is the Place of Pre-Exposure Prophylaxis in HIV Prevention?
    De Man, Jeroen
    Colebunders, Robert
    Florence, Eric
    Laga, Marie
    Kenyon, Christopher
    AIDS REVIEWS, 2013, 15 (02) : 102 - 111
  • [24] A Review of HIV Pre-exposure Prophylaxis Streamlining Strategies
    Aaron J. Siegler
    Kevin Steehler
    Jessica M. Sales
    Douglas S. Krakower
    Current HIV/AIDS Reports, 2020, 17 : 643 - 653
  • [25] A Review of HIV Pre-exposure Prophylaxis Streamlining Strategies
    Siegler, Aaron J.
    Steehler, Kevin
    Sales, Jessica M.
    Krakower, Douglas S.
    CURRENT HIV/AIDS REPORTS, 2020, 17 (06) : 643 - 653
  • [26] Preventing HIV Infection: Pre-exposure and Postexposure Prophylaxis
    Doblecki-Lewis, Susanne
    Kolber, Michael A.
    IUBMB LIFE, 2014, 66 (07) : 453 - 461
  • [27] A Review of HIV Pre-Exposure Prophylaxis: The Female Perspective
    Bailey, Jennifer L.
    Molino, Suzanne T.
    Vega, Ana D.
    Badowski, Melissa
    INFECTIOUS DISEASES AND THERAPY, 2017, 6 (03) : 363 - 382
  • [28] Tenofovir-based HIV pre-exposure prophylaxis
    Paxton, Lynn A.
    FUTURE VIROLOGY, 2013, 8 (12) : 1207 - 1218
  • [29] A Review of HIV Pre-Exposure Prophylaxis: The Female Perspective
    Jennifer L. Bailey
    Suzanne T. Molino
    Ana D. Vega
    Melissa Badowski
    Infectious Diseases and Therapy, 2017, 6 : 363 - 382
  • [30] Antiretroviral Drugs for Pre-Exposure Prophylaxis of HIV Infection
    Vicente Fernandez-Montero, Jose
    Barreiro, Pablo
    del Romero, Jorge
    Soriano, Vincent
    AIDS REVIEWS, 2012, 14 (01) : 54 - 61